The program combines career exploration with hands-on activities in classes that cost $15.

COMPASS Pathways is rated buy, with high risk, based on strong trial design and imminent FDA review for COMP360. Read more on CMPS stock here.

CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...

COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current ...

Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities. Lykos Therapeutics, a psychedelic ...

COMPASS Pathways has delivered a powerful 3 year share price gain, even after a recent pullback, and fresh clinical progress ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

COMPASS Pathways stock (ISIN US20451W1018) stood at USD 13.75 in after-hours trading on Nasdaq on September 23, 2026, down 6.97 percent from the previous close of USD 14.78. The move followed a TD ...